uniQure Submits BLA for AMT-130 Gene Therapy Targeting Huntington’s Disease

Gene therapy developer uniQure has officially filed a Biologics License Application with regulatory authorities for its experimental treatment AMT-130 aimed at halting Huntington’s disease progression.

2 Sept, 11:05 — 2 Sept, 11:05

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual1d ago

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease - Taiwan News

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease Taiwan News

Read full article →

uniQure Submits BLA for AMT-130 Gene Therapy Targeting Huntington’s Disease

Sources

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease - Taiwan News

Related Stories

UNICEF Report Reveals 20 Million Children Face Annual Online Sexual Exploitation

Genetically Modified Pig Kidney Sustains Patient for Record Nine Months

Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops

RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally